BeiGene Manufacturing and Clinical R&D Center, Phase I

BeiGene | Manufacturing and Clinical R&D Center, Phase I | Hopewell, NJ

Phase I at the Princeton West Innovation Center entails the construction of approximately 400,000-sq.-ft. of biologic pharmaceutical manufacturing space. DPR is self-performing select scopes of work. Leveraging our own forces helps alleviate workforce demands and the labor shortage across the AEC industry.

Customer

Quote

“At BeiGene, we are committed to not only delivering innovative and affordable medicines but also to upholding the highest standards of ethics and integrity, operational excellence, and environmental stewardship. This commitment applies to everything we do, including the development of BeiGene’s Hopewell project.”

John V. Oyler, Co-Founder, Chairman and CEO of BeiGene

We think you'll like this, too.
Related

Content

Polykon Manufacturing Facility

BioMarin Pharmaceutical

cGMP Manufacturing Facility

US Flagship Manufacturing and Clinical R&D Center Breaks Ground in New Jersey for BeiGene

Erytech Cell Therapy Manufacturing Facility

At NIH, Prefabrication Delivers Quality on Schedule

Confidential Pharmaceutical Client Development Center